all report title image
  • Published On : Feb 2022
  • Code : CMI4920
  • Industry : Pharmaceutical
  • Pages : 211
  • Formats :

Liver disease is either inherited (genetic) or is caused by factors that damage the liver such as viruses (hepatitis A, hepatitis B, and hepatitis C) and excessive alcohol consumption. Obesity is also associated with liver damage. Liver is an essential part of the body, which helps in digestion of food and controls the toxicity of substances in body. Cirrhosis is the result of liver damage, which can be life threatening and can lead to liver failure.  

The increasing prevalence of chronic liver diseases such as nonalcoholic fatty liver disease, hepatitis, and others, among large population base in the Middle East region due to lifestyle diseases such as obesity and type 2 diabetes mellitus (DM) and this is expected to drive demand for drugs used in liver disease treatment, thereby propelling the market growth.

Middle East and Turkey chronic liver disease (CLD) therapeutics market size is estimated to be valued at US$ 1,015 million in 2021 and is expected to exhibit a CAGR of 5.8% over the forecast period (2021-2028).

Figure 1. Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Value (US$ Mn), by Region/Country, 2021

Middle East & Turkey Chronic Liver Disease Therapeutic  | Coherent Market Insights

Figure 1.1 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Value (US$ Mn), by Region/Country, 2028

Middle East & Turkey Chronic Liver Disease Therapeutic  | Coherent Market Insights

CMI table icon

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 1,015 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 5.8% 2028 Value Projection: US$ 1,500 Mn
Geographies covered:
  • Middle East & Turkey: Turkey, Saudi Arabia, Israel, UAE, Egypt, and Rest of Middle East and Turkey
Segments covered:
  • By Disease Type: Hepatitis, Alcohol Induced Liver Disease, Liver Cancer, Fatty Liver Disease, Others
  • By Drug Class: Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulin, Others
  • By Route of Administration: Oral, Parenteral
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc., and Pfizer Inc.

Growth Drivers:
  • Increasing prevalence of chronic liver disease (CLD)
  • Growing geriatric population
  • Government and non-government awareness programs related to liver disease
Restraints & Challenges:
  • High cost in treatment of chronic liver disease

Figure 2. Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Share (%), by Drug Class, 2021

Middle East & Turkey Chronic Liver Disease Therapeutic  | Coherent Market Insights

Figure 2.1. Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Share (%), by Drug Class, 2028

Middle East & Turkey Chronic Liver Disease Therapeutic  | Coherent Market Insights

Chemotherapy Drugs segment is expected to hold largest market share in the Middle East and Turkey chronic liver disease (CLD) therapeutics market

Since cancer cells grow and multiply much faster than most of the cells in body, chemotherapy is most often utilized for cancer treatment. The increasing incidence of liver cancer and launch of novel products for cancer treatment are some of the factors, which are expected to drive the Chemotherapy Drugs segment growth. According to the International Agency for Research on Cancer (IARC), age-standardized incidence rate (ASIR) for liver cancer was 4.5 per 100,000 people in 2018 in Saudi Arabia.

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Restraint

High cost of treatment for chronic liver diseases is a major factor, which is expected to hinder the market growth. Furthermore, owing to this factor, a large patient pool suffering from CLD is unable to avail proper treatment. The treatment for chronic liver diseases include chemotherapy, targeted therapy, vaccines, immunoglobulin, and others, which are overpriced for the patients in low and middle income countries in the (Middle East and North Africa) MENA region. For instance, the cost of surgical treatment of liver cancer in Herzliya Medical Center, Israel, is US$ 25,000 and the cost of chemotherapy starts at US$ 3,500.

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 263,563,622 cases and 5,232,562 deaths due to coronavirus disease (COVID-19) were reported till December 03, 2021, across the globe.

Treatment options for cancer such as chemotherapy can weaken the immune system of cancer patients and increase the risk of getting infected. Hence, people suffering from cancer such as liver cancer are at higher risk of developing serious complications due to COVID-19 infection.

Moreover, healthcare providers are adopting telehealth solutions to conduct their services for patients with severe chronic liver disease while maintaining social distancing to combat COVID-19 pandemic without compromising the health of patients with chronic liver disease. Patients can arrange virtual appointments with their doctors for consultations. Healthcare providers are taking above mentioned measures to reduce the spread of COVID-19 infection.

Furthermore some studies also indicated that, COVID-19 was significantly associated with alcoholic liver damage. Nevertheless, impact of alcohol during COVID-19 within the alcohol consumption and ALD may impact COVID-19 pathogenesis.

Key Players

Major players operating in the Middle East and Turkey chronic liver disease (CLD) therapeutics market include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc, and Pfizer Inc.

Chronic liver disease is associated with the progressive destruction of liver parenchyma for longer period of time (6 months) leading to liver fibrosis and cirrhosis. The main etiology of CLD include alcohol induced liver, hepatitis virus (B, C, and D), hepatocellular carcinoma (HCC), liver cancer, and fatty liver diseases. The treatment for chronic liver diseases include chemotherapy, targeted therapy, vaccines, immunoglobulin, and others. Market players such as IceCure Medical, BioLineRx Ltd., Oramed Pharmaceuticals Inc., and BioLineRx Ltd. are engaged in the development of novel treatment options for CLD.

Middle East and Turkey chronic liver disease therapeutics market is estimated to be valued at US$ 1,015 Mn in 2021 and is expected to reach US$ 1,500 Mn by 2028, exhibiting a CAGR of 5.8% during the forecast period (2021-2028).

Market Dynamics

The increasing incidence of liver disease, growing geriatric population, Government and non-government awareness programs related to liver disease, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Middle East and Turkey chronic liver disease therapeutics market over the forecast period.

According to National Library of Medicine, in the Middle East, the prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, with associated risk factors including Obesity, and type 2 Diabetes. The patient’s progress to develop Nonalcoholic Steatohepatitis (NASH) is about 20% to 30%. Younossi, a nationally recognized leader specializing in hepatology and gastroenterology, reported that in Middle East the prevalence to be highest (33%) in a meta-analysis on Global Epidemiology of NAFLD. Awareness with suspected NAFLD has increased over last two decades, but 95% of the patients are still unaware about having liver disease.

Key features of the study:

  • This report provides an in-depth analysis of the Middle East and Turkey chronic liver Disease (CLD) therapeutics market, provides market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Middle East and Turkey chronic liver disease (CLD) therapeutics market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc., and Pfizer Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • Middle East and Turkey chronic liver disease (CLD) therapeutics market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Turkey chronic liver disease (CLD) therapeutics market

Detailed Segmentation:

  • Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Disease Type:
    • Hepatitis
    • Alcohol Induced Liver Disease
    • Liver Cancer
    • Fatty Liver Disease
    • Others
  • Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Drug Class:
    • Chemotherapy Drugs
    • Targeted therapy
    • Vaccines
    • Immunoglobulin
    • Others
  • Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Route of Administration:
    • Oral
    • Parenteral
  • Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Country:
    • Middle East
      • By Country:
        • Turkey
        • Saudi Arabia
        • Israel
        • UAE
        • Egypt
        • Rest of Middle East and Turkey
  • Company Profiles
    • Hoffmann-La Roche AG*
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Gilead Sciences, Inc.
    • Intercept Pharmaceuticals, Inc.
    • Swedish Orphan Biovitrum AB
    • GlaxoSmithKline Plc
    • Sanofi S.A
    • Teva Pharmaceutical Industries Ltd
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Abbott Laboratories
    • AstraZeneca plc.
    • Pfizer Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Middle East and Turkey chronic liver disease (CLD) therapeutics market size is expected to be valued at US$ 1,015 million in 2021 and is expected to exhibit a CAGR of 5.8% between 2021 and 2028.
Increasing prevalence of chronic liver disease (CLD), growing geriatric population, Government and non-government awareness programs related to liver disease are expected to drive the market growth.
Hepatitis segment is expected to hold a major market share in the market.
Chemotherapy Drugs segment is expected to hold the largest market share in the market.
Saudi Arabia is expected to hold the highest revenue share in market.  
High cost in treatment of chronic liver disease is a key factor that is expected to hamper growth of the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo